Imidazolines and Pancreatic Hormone Secretiona
- 1 June 1999
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 881 (1) , 217-228
- https://doi.org/10.1111/j.1749-6632.1999.tb09364.x
Abstract
A range of imidazoline derivatives are known to be effective stimulators of insulin secretion, and this response correlates with closure of ATP‐sensitive potassium channels in the pancreatic β‐cell. However, mounting evidence indicates that potassium channel blockade may form only part of the mechanism by which imidazolines exert their effects on insulin secretion. Additionally, it remains unclear whether members of this class of drugs can bind directly to potassium channel components and whether occupation of a single binding site accounts for their functional activity. This review considers recent developments in the field and highlights evidence that does not fit readily with the concept that a single mechanism of action is sufficient to mediate the effects of imidazolines on pancreatic hormone secretion.Keywords
This publication has 42 references indexed in Scilit:
- Potent antihyperglycaemic property of a new imidazoline derivative S-22068 (PMS 847) in a rat model of NIDDMBritish Journal of Pharmacology, 1998
- Stimulation of insulin release from the MIN6 cell line by a new imidazoline compound, S‐21663: evidence for the existence of a novel imidazoline site in β cellsBritish Journal of Pharmacology, 1997
- Association and Stoichiometry of KATP Channel SubunitsPublished by Elsevier ,1997
- Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with σ receptorsEuropean Journal of Pharmacology, 1997
- Characterization of the Imidazoline Binding Site Involved in Regulation of Insulin Secretionfn1Annals of the New York Academy of Sciences, 1995
- Imidazolines stimulate release of insulin from RIN-5AH cells independently from imidazoline I1 and I2 receptorsEuropean Journal of Pharmacology, 1994
- Section Review: Oncologic, Endocrine and Metabolic Adrenoceptors and imidazoline binding sites in the endocrine pancreas as targets for anti-hyperglycaemic drugsExpert Opinion on Investigational Drugs, 1994
- Stimulation of insulin secretion by the imidazoline α2-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding siteEuropean Journal of Pharmacology, 1993
- The α2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cellsEuropean Journal of Pharmacology, 1991
- Studies of midaglizole (DG-5128). A new type of oral hypoglycemic drug in healthy subjectsDiabetes, 1987